Erne, Eva
Kruck, Stephan
Todenhoefer, Tilman
Aufderklamm, Stefan
Amend, Bastian
Bedke, Jens
Stenzl, Arnulf
Rausch, Steffen http://orcid.org/0000-0002-6398-8701
Funding for this research was provided by:
Projekt DEAL
Article History
Received: 14 September 2020
Accepted: 13 January 2021
First Online: 16 February 2021
Compliance with ethical standards
:
: Arnulf Stenzl reports grants from Johnson & Johnson, grants from Amgen, Inc., other from Bayer AG, other from CureVac, other from Immatics Biotechnologies GmbH, grants from Immatics Biotechnologies GmbH, grants from Novartis AG, grants from Karl Storz AG, during the conduct of the study; personal fees from Ipsen Pharma, personal fees from Janssen, personal fees from Alere, personal fees from Janssen, personal fees from Ipsen Pharma, outside the submitted work. Eva Erne, Stephan Kruck, Tilman Todenhoefer, Bastian Amend, Stefan Aufderklamm, Jens Bedke and Steffen Rausch have no conflicts of interest or financial ties to declare.